• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    1/12/26 4:03:49 PM ET
    $NTRA
    Medical Specialities
    Health Care
    Get the next $NTRA alert in real time by email
    false 0001604821 0001604821 2026-01-11 2026-01-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of

    the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): January 11, 2026

     

     

     

    Natera, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-37478   01-0894487

    (State or other jurisdiction
    of incorporation)

     

    (Commission
    File Number)

     

    (IRS Employer
    Identification No.)

     

    13011 McCallen Pass
    Building A Suite 100

    Austin, TX 78753

    (Address of principal executive offices, including zip code)

     

    (650) 980-9190

    (Registrant’s telephone number, including area code)

     

    N/A

    (Former name or former address, if changed since last report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   NTRA   Nasdaq Stock Market LLC
    (Nasdaq Global Select Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

     

    Item 2.02. Results of Operations and Financial Condition.

     

    On January 11, 2026, Natera, Inc. (the “Company”) issued a press release announcing preliminary financial results for its fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

    The information in this Current Report on Form 8-K and the accompanying Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by reference in such filing.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description  
    99.1   Press Release dated January 11, 2026.
    104   Cover Page Interactive Data File (formatted as inline XBRL).

     

     

     

      

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Natera, Inc.
         
      By: /s/ Michael Brophy
        Michael Brophy
        Chief Financial Officer (Principal Financial and Accounting Officer)

     

    Dated: January 12, 2026

     

     

     

    Get the next $NTRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTRA

    DatePrice TargetRatingAnalyst
    1/7/2026$300.00Buy
    Citigroup
    12/2/2025$265.00Overweight
    Morgan Stanley
    10/27/2025$172.00Underperform → Neutral
    BNP Paribas Exane
    9/22/2025$175.00Equal Weight
    Wells Fargo
    3/13/2025$251.00Outperform
    RBC Capital Mkts
    1/23/2025$200.00Overweight
    Barclays
    6/3/2024$142.00Buy
    Jefferies
    4/8/2024$117.00Buy
    Craig Hallum
    More analyst ratings

    $NTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO AND PRESIDENT Chapman Steven Leonard was granted 152,718 shares, increasing direct ownership by 112% to 289,286 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    1/16/26 9:05:13 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC. AND CHIEF LEGAL OFFICER Rabinowitz Daniel was granted 37,248 shares, increasing direct ownership by 18% to 245,849 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    1/16/26 9:05:06 PM ET
    $NTRA
    Medical Specialities
    Health Care

    CO-FOUNDER Sheena Jonathan was granted 7,450 shares, increasing direct ownership by 3% to 270,031 units (SEC Form 4)

    4 - Natera, Inc. (0001604821) (Issuer)

    1/16/26 9:05:05 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling

    New AI-derived model integrates longitudinal ctDNA and clinical data with digital pathology and tumor sequencing data, to refine recurrence risk assessment and outcomes prediction Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced an advancement in molecular residual disease (MRD)-based risk stratification that is expected to extend the company's leadership in oncology. The new multi-modal model will integrate longitudinal ctDNA and clinical data with digital pathology imaging and tumor sequencing data, to enhance the Signatera™ MRD assessment. Signatera has transformed cancer management by enabling ultra-sensitive MRD de

    1/13/26 8:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a new collaboration with NVIDIA to accelerate the development of Natera's multimodal AI foundation model platform and expand applications across precision medicine. Under the collaboration, Natera will integrate its unique longitudinal and multi-time point in vivo datasets and proprietary machine learning models with NVIDIA's high-performance computing platforms, accelerated libraries, and AI frameworks. Together, the companies aim to establish the computational infrastructure required to train and deploy large scale AI models on complex medical datasets, enabling more precise diag

    1/12/26 10:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth

    2025 revenues are expected to increase by approximately 35% compared to 2024, which is approximately $40 million above the top end of Natera's financial outlook Additional business updates will be presented at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today released preliminary unaudited results for the fourth quarter and full year ended December 31, 2025. The Company expects the following: Total revenues of approximately $660 million in the fourth quarter of 2025 compared to $476 million in the fourth quarter of 2024, an increase of approximately 39%. Total revenues, excl

    1/11/26 10:48:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    SEC Filings

    View All

    Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Natera, Inc. (0001604821) (Filer)

    1/12/26 4:03:49 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form 144 filed by Natera Inc.

    144 - Natera, Inc. (0001604821) (Subject)

    1/2/26 4:13:25 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form 144 filed by Natera Inc.

    144 - Natera, Inc. (0001604821) (Subject)

    12/12/25 10:07:26 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Natera with a new price target

    Citigroup initiated coverage of Natera with a rating of Buy and set a new price target of $300.00

    1/7/26 9:12:45 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Morgan Stanley resumed coverage on Natera with a new price target

    Morgan Stanley resumed coverage of Natera with a rating of Overweight and set a new price target of $265.00

    12/2/25 8:28:19 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Natera from Underperform to Neutral and set a new price target of $172.00

    10/27/25 9:03:32 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Leadership Updates

    Live Leadership Updates

    View All

    Octave Bioscience Expands Leadership Team with Appointment of Kirk Stockwood Senior Vice President, Commercial

    Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker driven solutions for multiple sclerosis, Parkinson's disease and other neurodegenerative diseases today announced the appointment of Kirk Stockwood as Senior Vice President, Commercial. Mr. Stockwood will spearhead Octave's commercial strategy as the company scales operations and expands the reach of its precision neurology platform. Mr. Stockwood brings over 20 years of leadership experience in specialty diagnostics and tools, with a proven track record of commercial scaling within public and private companies. Most recently as Vice President of Sales at Quanterix, he led a global team focused on

    1/8/26 4:01:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Experienced Biotech Executive and Deal Maker Joins Zephyr AI as Chief Business Officer

    Zephyr AI, Inc. ("Zephyr AI"), a company building novel transparent AI to address unmet needs across the full spectrum of precision medicine – from prevention to treatment – to improve patients' lives, today announced the appointment of Eric Lindquist as its new Chief Business Officer. "At Zephyr AI, we have set out to use artificial intelligence and machine learning to bring precision medicine to those suffering from cancer, and our goal is for patients everywhere to be able to find the right treatment, delivered by the right provider, when they need it, enabling them to live healthier and fuller lives," said Grant Verstandig, Co-Founder and Executive Chairman of Zephyr AI. "Eric has bee

    6/5/23 11:06:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Appoints Ruth E. Williams-Brinkley to its Board of Directors

    Seasoned healthcare executive with extensive leadership experience in health plans, hospital operations, and physician relations Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing, today announced that Ruth E. Williams-Brinkley has been appointed to the Company's board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005436/en/(Photo: Business Wire) Williams-Brinkley has three decades of healthcare industry experience. She currently serves as president of Kaiser Permanente Health Plan of the Mid-Atlantic States (KPMAS), where she oversees the company's care delivery and health plan operations

    2/23/23 8:05:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Financials

    Live finance-specific insights

    View All

    Natera Acquires Foresight Diagnostics

    Expands Natera's lead in solid tumor MRD, acquiring ultrasensitive phased variant technology with LOD95 of 0.3 parts per million (ppm) and detection below 0.1 ppm1 Cutting-edge IP adds to Natera's portfolio of >500 issued or pending patents Accelerates Natera's expansion into lymphoma, where Foresight has developed a strong clinical position Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, today announced that Natera has completed a transaction to acquire Foresight. Foresight is a cancer diagnostics company and CLIA-registered laboratory. The company's ci

    12/5/25 7:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera Reports Third Quarter 2025 Financial Results

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today reported its financial results for the third quarter ended September 30, 2025. Recent Financial Highlights Generated total revenues of $592.2 million in the third quarter of 2025, compared to $439.8 million in the third quarter of 2024, an increase of 34.7%. Product revenues grew 35.3% over the same period. Generated a gross margin percentage2 of 64.9% in the third quarter of 2025, compared to a gross margin percentage2 of 61.8% in the third quarter of 2024. Processed approximately 893,600 tests in the third quarter of 2025, compared to approximately 775,800 tests in the third quarter of 2024,

    11/6/25 4:05:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Natera to Report its Third Quarter Results on November 6, 2025

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its third quarter ended September 30, 2025, after the market closes on November 6, 2025. Natera will host a conference call and webcast shortly thereafter at 4:30 p.m. ET. Earnings Conference Call Information Event: Natera's Third Quarter 2025 Financial Results Date: November 6, 2025 Time: 4:30 p.m. ET Live Dial-In: 1-888-770-7321 (Domestic)   1-929-201-7107 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/attendee/822764987

    10/30/25 7:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    $NTRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Natera Inc.

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    11/14/24 4:02:50 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    6/7/24 12:07:25 PM ET
    $NTRA
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Natera Inc. (Amendment)

    SC 13G/A - Natera, Inc. (0001604821) (Subject)

    2/14/24 4:06:56 PM ET
    $NTRA
    Medical Specialities
    Health Care